Browse 44 Market Data Tables and 39 Figures spread through 218 Pages and in-depth TOC on "Low Molecular Weight Heparin Market, by Drug (
Enoxaparin, Dalteparin, Nadroparin, Bemiparin, Tinzaparin, and Others), by Packaging (Multi-vials and Prefilled Syringes), by Application (Deep Vein Thrombosis, Acute Coronary Syndrome (ACS), Pulmonary Embolism, and Atrial Fibrillation), by End Use (Hospitals (Private and Public), Clinics, and Home), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026"
The results showed that while both types of blood thinners prevented clots, 80 percent of patients receiving
enoxaparin had minor bleeding during surgery, which correlated with theETP measurement.
Enoxaparin, a low-molecular-weight heparin, has anticoagulant and antithrombotic effects during PCI with no need of repeatedly monitoring ACT due to its longer half-life (3.5-4.5 h).
Conclusion: Low-molecular-weight heparin (
enoxaparin) is safe for use in conjunction with indwelling epidural catheter if appropriate interval is provided for catheter insertion and removal.
We retrospectively analysed our data for short term outcome of efficacy and safety with use of
enoxaparin as procedural anticoagulant.
The thicker subcutaneous tissue (>25 mm) and larger surface area of the abdominal wall are believed to reduce the risk of extravasation of
enoxaparin (Avsar & Kasikci, 2013).
They were randomly assigned to receive one daily subcutaneous injection of 40 mg
enoxaparin or placebo until 35 weeks' gestation.
Preparation of Chitosan-PCL Nanoparticles with
Enoxaparin. Nanoparticles were prepared with a biodegradable polymer PCL (Aldrich) and coated with the natural polymer chitosan (105 g/mol/~81% acetylation, Polymar).
Enoxaparin, low molecular weight heparins(LMWH), isused for the treatment and prophylaxis of thrombosis.
This article will address three LMWHs:
enoxaparin, dalteparin, and tinzaparin.
Another important finding was that excessive uterine bleeding was more than twice as common among women taking rivaroxaban as among those taking
enoxaparin plus vitamin K antagonists.